PEGAPTANIB: 32 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
32
Total FAERS Reports
6 (18.8%)
Deaths Reported
2
Hospitalizations
32
As Primary/Secondary Suspect
2
Life-Threatening
1
Disabilities
Dec 17, 2004
FDA Approved
Discontinued
Status
Active Ingredient: PEGAPTANIB SODIUM · FDA Application: 021756 ·
First Report: 201302 · Latest Report: 20180510
What Are the Most Common PEGAPTANIB Side Effects?
#1 Most Reported
Off label use
8 reports (25.0%)
#2 Most Reported
Death
5 reports (15.6%)
#3 Most Reported
Ischaemic stroke
3 reports (9.4%)
All PEGAPTANIB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 8 | 25.0% | 0 | 0 |
| Death | 5 | 15.6% | 5 | 0 |
Who Reports PEGAPTANIB Side Effects? Age & Gender Data
Gender: 60.9% female, 39.1% male. Average age: 73.3 years. Most reports from: US. View detailed demographics →
Is PEGAPTANIB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2013 | 4 | 1 | 0 |
| 2014 | 1 | 1 | 1 |
| 2015 | 5 | 2 | 0 |
| 2017 | 2 | 0 | 0 |
| 2018 | 1 | 0 | 1 |
What Is PEGAPTANIB Used For?
| Indication | Reports |
|---|---|
| Age-related macular degeneration | 13 |
| Neovascular age-related macular degeneration | 7 |
| Diabetic retinal oedema | 5 |
| Diabetic retinopathy | 5 |
Official FDA Label for PEGAPTANIB
Official prescribing information from the FDA-approved drug label.